Search

Search Constraints

You searched for: Author/Creator Lord, Christopher J

Search Results

1. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Issue 11 (13th November 2021)

2. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Issue 11 (13th September 2021)

3. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. Issue 5 (5th February 2014)

6. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Issue 10 (22nd August 2017)

7. MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA. (4th December 2020)

8. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. (20th July 2018)

10. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. Issue 3 (25th January 2013)